Replimune Group, Inc. (REPL) Form 10-Q Quarterly Reports
Replimune Group, Inc. (REPL) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: REPL
CIK: 1737953
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 03/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
PricewaterhouseCoopers LLP
Auditor SinceSince 3/31/2018 12:00:00 AM
Lead Engagement PartnerChristopher Kean
Audit LocationFlorham Park, New Jersey, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-09-16 | 2026-09-15 | FORM 8-K | 0001104659-26-108243 | View SEC Doc Filr Page |
| 4 | 2026-08-24 | 2026-08-20 | OWNERSHIP DOCUMENT | 0001104659-26-100437 | View SEC Doc Filr Page |
| 4 | 2026-08-19 | 2026-08-17 | OWNERSHIP DOCUMENT | 0001104659-26-098868 | View SEC Doc Filr Page |
| S-3ASR | 2026-08-14 | — | S-3ASR | 0001104659-26-097309 | View SEC Doc Filr Page |
| 10-Q | 2026-08-14 | 2026-06-30 | 10-Q | 0001628280-26-057099 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001104659-26-097040 | View SEC Doc Filr Page |
| 8-K | 2026-08-14 | 2026-08-14 | FORM 8-K | 0001104659-26-096483 | View SEC Doc Filr Page |
| 4 | 2026-08-12 | 2026-08-10 | OWNERSHIP DOCUMENT | 0001104659-26-095012 | View SEC Doc Filr Page |
| 4 | 2026-08-12 | 2026-08-10 | OWNERSHIP DOCUMENT | 0001104659-26-095008 | View SEC Doc Filr Page |
| 4 | 2026-08-12 | 2026-08-10 | OWNERSHIP DOCUMENT | 0001104659-26-095006 | View SEC Doc Filr Page |
| 4 | 2026-08-12 | 2026-08-10 | OWNERSHIP DOCUMENT | 0001104659-26-095003 | View SEC Doc Filr Page |
| SCHEDULE 13D/A | 2026-08-11 | — | SCHEDULE 13D/A Filing | 0001104659-26-094196 | View SEC Doc Filr Page |
| 4 | 2026-08-11 | 2026-08-11 | 4 | 0001193125-26-345144 | View SEC Doc Filr Page |
| 8-K/A | 2026-08-11 | 2026-08-09 | FORM 8-K/A | 0001104659-26-093512 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-08-10 | — | SCHEDULE 13G Filing | 0000886982-26-000320 | View SEC Doc Filr Page |
| 8-K | 2026-08-10 | 2026-08-09 | FORM 8-K | 0001104659-26-093042 | View SEC Doc Filr Page |
| 424B5 | 2026-08-10 | — | 424B5 | 0001104659-26-093040 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-08-07 | — | SCHEDULE 13G Filing | 0000093751-26-000533 | View SEC Doc Filr Page |
| 8-K | 2026-08-07 | 2026-08-06 | FORM 8-K | 0001104659-26-092246 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-06 | — | SCHEDULE 13G/A Filing | 0000919574-26-004843 | View SEC Doc Filr Page |
| 8-K | 2026-07-31 | 2026-07-30 | FORM 8-K | 0001104659-26-088857 | View SEC Doc Filr Page |
| 8-K | 2026-07-30 | 2026-07-30 | FORM 8-K | 0001104659-26-088481 | View SEC Doc Filr Page |
| EFFECT | 2026-07-29 | — | EFFECT Filing | 9999999995-26-002486 | View SEC Doc Filr Page |
| ARS | 2026-07-29 | 2026-03-31 | ARS | 0001104659-26-087654 | View SEC Doc Filr Page |
| DEFA14A | 2026-07-29 | — | DEFA14A | 0001104659-26-087651 | View SEC Doc Filr Page |